Astellas takes $760M charge, reveals slowdown for eye drug Izervay after regulatory stumbles
The company is in talks with individual regulatory authorities after its decision to withdraw a European approval application for Izervay prompted a $760 million impairment charge.
The company is in talks with individual regulatory authorities after its decision to withdraw a European approval application for Izervay prompted a $760 million impairment charge.
